EVNIN LUKE 4

What Happened

• Luke Evnin, a director of Werewolf Therapeutics (HOWL), reported sales of 143,199 common shares in two open‑market/ private sale transactions under a Rule 10b5‑1 plan. On 2026-07-06 he disposed of 35,770 shares at a weighted average price of $0.32 for ~$11,446, and on 2026-07-07 he disposed of 107,429 shares at a weighted average price of $0.31 for ~$33,303. Total proceeds were about $44,749. These sales were effected through affiliated investment vehicles rather than direct personal sales.

Key Details

• Transaction dates: July 6, 2026 (35,770 shares, WAP $0.32) and July 7, 2026 (107,429 shares, WAP $0.31).
• Price ranges reported: 7/6 sales at $0.3128–$0.3388; 7/7 sales at $0.295–$0.3342. Reported column prices are weighted averages; per‑price detail is available on request.
• Total shares sold: 143,199; approximate total proceeds: $44,749.
• Holdings after transactions: the filing indicates no shares remain held by the listed affiliated entities (i.e., no remaining shares held by AM LLC, BV 2014, BV 2014(B), AM BV2014, or MPM OIF).
• Footnotes: Sales were made pursuant to a Rule 10b5‑1 plan established March 26, 2026. Evnin is a member/manager of the selling entities and disclaims beneficial ownership except to the extent of his pecuniary interest.
• Filing timeliness: Form 4 was filed July 8, 2026 reporting transactions on July 6–7; the filing shows no indication of a late report.

Context

• These are sales (not purchases), commonly interpreted as liquidity or portfolio management rather than a bullish signal. The trades were executed through affiliated funds and under a prearranged 10b5‑1 plan, which often governs timing and amounts of sales to avoid timing based on material nonpublic information.